Phase i study protocol for Ex vivo lentiviral gene therapy for the inherited skin disease, netherton syndrome

Human Gene Therapy Clinical Development

Volumn 24, Issue 4, 2013, Pages 182-190

  Di, Wei Li ^a   Mellerio, Jemima E ^b   Bernadis, Catina ^c   Harper, John ^a   Abdul Wahab, Alya ^b   Ghani, Sumera ^a   Chan, Lucas ^b   Martinez Queipo, Magdalena ^b   Hara, Havinder ^a   McNicol, Anne Marie ^a   Farzaneh, Farzin ^b   McGrath, John ^b   Thrasher, Adrian ^a   Qasim, Waseem ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; IMMUNOGLOBULIN E; LENTIVIRUS VECTOR; LYMPHOEPITHELIAL KAZAL TYPE RELATED INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ATOPY; CELLULAR IMMUNITY; CLINICAL PROTOCOL; DRUG SAFETY; ENZYME ASSAY; EPIDERMOLYSIS BULLOSA; EX VIVO GENE TRANSFER; FOLLOW UP; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; KERATINIZATION; NETHERTON DISEASE; OPEN READING FRAME; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN BLEEDING; SURGICAL INFECTION; VIRAL GENE DELIVERY SYSTEM;

CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; GENETIC THERAPY; HUMANS; KERATINOCYTES; LENTIVIRUS; MALE; NETHERTON SYNDROME; PROTEINASE INHIBITORY PROTEINS, SECRETORY;

EID: 84907241768     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2013.195     Document Type: Article

References (37)

1. Aiuti, A., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151.
2. Biffi, A., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158.
3. Bitoun, E., et al. (2003). LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum. Mol. Genet. 12, 2417-2430. (Pubitemid 37220407)
4. Bonnart, C., et al. (2010). Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Neth-erton syndrome through filaggrin and lipid misprocessing. J. Clin. Invest. 120, 871-882.
5. Briot, A., et al. (2009). Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoie-tin expression in Netherton syndrome. J. Exp. Med. 206, 1135-1147.
6. Cavazza, A., and Mavilio, F. (2012). Gene therapy of skin adhesion disorders (mini review). Curr. Pharm. Biotechnol. 13, 1868-1876.
7. Cavazzana-Calvo, M., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322.
8. Chavanas, S., et al. (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25, 141-142. (Pubitemid 30394980)
9. Choate, K.A., Medalie, D.A., Morgan, J.R., and Khavari, P.A. (1996). Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nat. Med. 2, 1263-1267. (Pubitemid 26375415)
10. Deraison, C., et al. (2007). LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 18, 3607-3619. (Pubitemid 47378698)
11. Di, W.L., et al. (2011). Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther. 19, 408-416.
12. Di, W.L., et al. (2012). Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression. Hum. Gene Ther. 23, 83-90.
13. Egelrud, T., et al. (2005). hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br. J. Dermatol. 153, 1200-1203. (Pubitemid 41779577)
14. Fenjves, E.S., Yao, S.N., Kurachi, K., and Taichman, L.B. (1996). Loss of expression of a retrovirus-transduced gene in human keratinocytes. J. Invest. Dermatol. 106, 576-578.
15. Gagnoux-Palacios, L., et al. (2005). Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J. Gene Med. 7, 1178-1186. (Pubitemid 41335170)
16. Gerrard, A.J., Hudson, D.L., Brownlee, G.G., and Watt, F.M. (1993). Towards gene therapy for haemophilia B using primary human keratinocytes. Nat. Genet. 3, 180-183. (Pubitemid 23079803)
17. Ghazizadeh, S., Doumeng, C., and Taichman, L.B. (2002). Durable and stratum-specific gene expression in epidermis. Gene Ther. 9, 1278-1285.
18. Hacein-Bey-Abina, S., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419. (Pubitemid 37296260)
19. Hacein-Bey-Abina, S., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
20. Hernon, C.A., et al. (2006). Clinical experience using cultured epithelial autografts leads to an alternative methodology for transferring skin cells from the laboratory to the patient. Regen. Med. 1, 809-821.
21. Howe, S.J., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
22. Jayakumar, A., et al. (2004). Expression of LEKTI domains 6-9¢ in the baculovirus expression system: recombinant LEKTI domains 6-9¢ inhibit trypsin and subtilisin A. Protein Expr. Purif. 35, 93-101. (Pubitemid 38497911)
23. Komatsu, N., et al. (2002). Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol. 118, 436-443. (Pubitemid 34227160)
24. Kuhn, U., et al. (2002). In vivo assessment of gene delivery to keratinocytes by lentiviral vectors. J. Virol. 76, 1496-1504. (Pubitemid 34066449)
25. MacNeil, S. (2007). Progress and opportunities for tissue-engineered skin. Nature 445, 874-880.
26. Magert, HJ., et al. (1999). LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J. Biol. Chem. 274, 21499-21502.
27. Marchetto, M.C., Correa, R.G., Menck, C.F., and Muotri, A.R. (2006). Functional lentiviral vectors for xeroderma pigmento-sum gene therapy. J. Biotechnol. 126, 424-430. (Pubitemid 44634821)
28. Mavilio, F., et al. (2006). Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12, 1397-1402. (Pubitemid 44924498)
29. Mitsudo, K., et al. (2003). Inhibition of serine proteinases plas-min, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry 42, 3874-3881. (Pubitemid 36402680)
30. Montini, E., et al. (2002). In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol. Ther. 6, 759-769. (Pubitemid 36054309)
31. Montini, E., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-696. (Pubitemid 43882120)
32. Moustafa, M., et al. (2004). A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabet. Med. 21, 786-789. (Pubitemid 38916227)
33. Ott, M.G., et al. (2006). Correction of X-linked chronic granulo-matous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
34. Rheinwald, J.G. (1989). Methods for clonal growth and serial cultuvation of normal human epidermal keratinocytes and mesothelial cells. In A Practical Approach. R. Baserga, ed. (IRL Press, Oxford), pp. 81-94.
35. Sales, K.U., et al. (2010). Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat. Genet. 42, 676-683.
36. Uitto, J., Christiano, A.M., McLean, W.H., and McGrath, J.A. (2012). Novel molecular therapies for heritable skin disorders. J. Invest. Dermatol. 132, 820-828.
37. Watt, F.M. (2002). The stem cell compartment in human inter-follicular epidermis. J. Dermatol. Sci. 28, 173-180. (Pubitemid 34242651)